TELO Stock Overview
A pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells.
Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 0/6 |
Telomir Pharmaceuticals, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$5.25 |
52 Week High | US$20.72 |
52 Week Low | US$4.76 |
Beta | 0 |
11 Month Change | -22.11% |
3 Month Change | -5.41% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | 5.00% |
Recent News & Updates
Recent updates
Shareholder Returns
TELO | US Pharmaceuticals | US Market | |
---|---|---|---|
7D | -4.5% | 1.0% | 0.5% |
1Y | n/a | 17.7% | 23.9% |
Return vs Industry: Insufficient data to determine how TELO performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how TELO performed against the US Market.
Price Volatility
TELO volatility | |
---|---|
TELO Average Weekly Movement | 18.5% |
Pharmaceuticals Industry Average Movement | 9.6% |
Market Average Movement | 5.7% |
10% most volatile stocks in US Market | 15.4% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: TELO's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine TELO's volatility change over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2021 | 5 | Chris Chapman | telomirpharma.com |
Telomir Pharmaceuticals, Inc., a pre-clinical-stage pharmaceutical company, focuses on the development and commercialization of therapeutic treatment for human stem cells. The company develops TELOMIR-1, a novel small molecule being developed to function as an oral in situ therapeutic intervention against age-related inflammatory conditions, such as hemochromatosis and osteoarthritis, as well as for post-chemotherapy health problems. The company was formerly known as Metallo Therapies Inc. and changed its name to Telomir Pharmaceuticals, Inc. in October 2022.
Telomir Pharmaceuticals, Inc. Fundamentals Summary
TELO fundamental statistics | |
---|---|
Market cap | US$155.45m |
Earnings (TTM) | -US$18.84m |
Revenue (TTM) | n/a |
0.0x
P/S Ratio-8.2x
P/E RatioIs TELO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TELO income statement (TTM) | |
---|---|
Revenue | US$0 |
Cost of Revenue | US$0 |
Gross Profit | US$0 |
Other Expenses | US$18.84m |
Earnings | -US$18.84m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.64 |
Gross Margin | 0.00% |
Net Profit Margin | 0.00% |
Debt/Equity Ratio | 0.3% |
How did TELO perform over the long term?
See historical performance and comparison